New combo therapy aims to keep cancer-fighting cells from burning out
NCT ID NCT06389305
First seen Feb 26, 2026 · Last updated May 05, 2026 · Updated 9 times
Summary
This study looks at whether adding cytokine-induced killer (CIK) cells can prevent CAR-T cells from wearing out too early in people with relapsed or refractory B-cell acute lymphoblastic leukemia. About 213 children and young adults will be randomly assigned to receive either standard care, CIK cells, or enhanced CIK cells. The main goal is to see if CIK therapy improves how long patients stay cancer-free without relapse or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.